1,000.00p+30.00 (+3.09%)05 Aug 2025, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

4Basebio PLC Fundamentals

Company Name4Basebio PLCLast Updated2025-08-05
IndustryBiotechnologySectorHealthcare
Shares in Issue15.485 mMarket Cap£154.85 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.94EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.3402Debt Equity Ratio0.5697
Asset Equity Ratio1.6955Cash Equity Ratio1.3118
Quick Ratio10.6851Current Ratio11.30
Price To Book Value5.6948ROCE0

4Basebio PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

4Basebio PLC Company Financials

Assets202420232022
Tangible Assets£4.33 m£4.20 m£3.63 m
Intangible Assets£3.48 m£2.67 m£2.12 m
Investments000
Total Fixed Assets£7.84 m£6.90 m£5.79 m
Stocks£374,000.00£332,000.00£133,000.00
Debtors£283,000.00£107,000.00£54,000.00
Cash & Equivalents£34.60 m£3.07 m£4.35 m
Other Assets000
Total Assets£44.73 m£11.92 m£11.69 m
Liabilities202420232022
Creditors within 1 year£3.27 m£2.28 m£1.52 m
Creditors after 1 year£15.08 m£10.14 m£3.05 m
Other Liabilities000
Total Liabilities£18.35 m£12.41 m£4.57 m
Net assets£26.38 m-£492,000.00£7.12 m
Equity202420232022
Called up share capital£13.77 m£11.13 m£11.13 m
Share Premium£37.25 m£706,000.00£706,000.00
Profit / Loss-£12.65 m-£8.35 m-£5.93 m
Other Equity£26.38 m-£492,000.00£7.12 m
Preference & Minorities000
Total Capital Employed£26.38 m-£492,000.00£7.12 m
Ratios202420232022
Debt Ratio£0.360£0.29
Debt-to-Equity£0.570£0.41
Assets / Equity1.69551.69551.6955
Cash / Equity1.31181.31181.3118
EPS-£0.94-£0.62-£0.42
Cash Flow202420232022
Cash from operating activities-£10.74 m-£6.18 m-£4.70 m
Cashflow before financing£33.12 m£247,000.00-£3.46 m
Increase in Cash£31.55 m-£1.24 m-£5.40 m
Income202420232022
Turnover£933,000.00£506,000.00£268,000.00
Cost of sales£303,000.00£166,000.00£29,000.00
Gross Profit£630,000.00£340,000.00£239,000.00
Operating Profit-£12.04 m-£8.05 m-£5.84 m
Pre-Tax profit-£12.65 m-£8.35 m-£5.93 m

4Basebio PLC Company Background

SectorHealthcare
Activities4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Latest Interim Date27 Sep 2024
Latest Fiscal Year End Date27 May 2025

4Basebio PLC Directors

AppointedNamePosition
2025-07-08Mr. Timothy Paul McCarthyNon-Executive Director,Chairman
2025-05-30Dr. Joseph M. FernandezNon-Executive Director
2024-06-28Mr. Hansjorg PlaggemarsNon-Executive Director
2025-04-04Dr. Heikki Lanckriet, PhDExecutive Director,Chief Executive Officer
2024-09-21Mr. David John RothExecutive Director,Chief Financial Officer and Company Secretary
2025-03-03Dr. Amy Jo WalkerExecutive Director,Chief Operating Officer

4Basebio PLC Contact Details

Company Name4basebio PLC
Address25 Norman Way, Over, Cambridge, CB24 5QE
Telephone+44 1223967943
Websitehttps://www.4basebio.com

4Basebio PLC Advisors